** Shares of life sciences firm Danaher DHR.N fall 5.2% to $235 premarket

** DHR posts Q4 EPS of $2.14, below analysts' estimates of $2.16, according to LSEG data, due to weak demand from biotech and pharmaceutical clients

** Forecasts Q1 2025 adjusted core revenue to "decline low-single digits year-over-year"

** DHR's diagnostics business posts sales of $2.64 bln vs. analysts' est. of $2.55 bln - LSEG

** Life sciences unit posts sales of $2.03 bln vs. analysts' est. of $1.96 bln - LSEG

** DHR reports Q4 sales of $6.54 bln vs. analysts' est. of $6.43 bln - LSEG

** Forecasts FY 2025 adjusted core rev. to increase about 3% year-over-year

** DHR fell 2.2$ in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))